| 15.1 Primary: BPD symptom severity at end of treatment (continuous outcome, MDs) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.1.1 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
8.48 [3.39, 13.57] |
| 15.2 Primary: Self‐harm at end of treatment (continuous outcome, MDs) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.2.1 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
2.55 [0.98, 4.12] |
| 15.3 Primary: Suicide‐related outcomes at end of treatment (continuous outcome, MDs) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.3.1 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
0.23 [‐0.74, 1.20] |
| 15.4 Primary: Psychosocial functioning at end of treatment (continuous outcome, MDs) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.4.1 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
0.88 [‐6.21, 7.97] |
| 15.5 Secondary: Anger at end of treatment (continuous outcome, MDs) |
2 |
89 |
Mean Difference (IV, Fixed, 95% CI) |
0.64 [‐0.77, 2.04] |
| 15.5.1 Olanzapine versus olanzapine plus fluoxetine |
1 |
29 |
Mean Difference (IV, Fixed, 95% CI) |
0.46 [‐12.93, 13.85] |
| 15.5.2 Fluoxetine versus fluoxetine plus olanzapine |
1 |
26 |
Mean Difference (IV, Fixed, 95% CI) |
4.77 [‐9.67, 19.21] |
| 15.5.3 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
0.60 [‐0.82, 2.02] |
| 15.6 Secondary: Affective instability at end of treatment (continuous outcome, MDs) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.6.1 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
1.72 [0.68, 2.76] |
| 15.7 Secondary: Chronic feelings of emptiness at end of treatment (continuous outcome, MDs) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.7.1 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
0.03 [‐0.97, 1.03] |
| 15.8 Secondary: Impulsivity at end of treatment (continuous outcome, MDs) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.8.1 Olanzapine versus olanzapine plus fluoxetine |
1 |
29 |
Mean Difference (IV, Fixed, 95% CI) |
0.46 [‐12.93, 13.85] |
| 15.8.2 Fluoxetinge versus fluoxetine plus olanzapine |
1 |
26 |
Mean Difference (IV, Fixed, 95% CI) |
4.77 [‐9.67, 19.21] |
| 15.8.3 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
12.59 [6.11, 19.07] |
| 15.9 Secondary: Interpersonal problems at end of treatment (continuous outcome, MDs) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.9.1 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
0.47 [‐0.41, 1.35] |
| 15.10 Secondary: Abandonment at end of treatment (continuous outcome, MDs) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.10.1 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
0.01 [‐0.83, 0.85] |
| 15.11 Secondary: Identity disturbance at end of treatment (continuous outcome, MDs) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.11.1 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
0.70 [‐0.34, 1.74] |
| 15.12 Secondary: Dissociation and psychotic‐like symptoms at end of treatment (continuous outcome, MDs) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.12.1 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
0.03 [‐1.09, 1.15] |
| 15.13 Secondary: Depression at end of treatment (continuous outcome, MDs) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.13.1 Olanzapine versus olanzapine plus fluoxetine |
1 |
29 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.78 [‐6.48, 2.92] |
| 15.13.2 Fluoxetine versus fluoxetine plus olanzapine |
1 |
26 |
Mean Difference (IV, Fixed, 95% CI) |
3.62 [‐1.36, 8.60] |
| 15.13.3 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
1.30 [0.00, 2.60] |
| 15.14 Secondary: Attrition at end of treatment (dichotomous outcomes, RRs) |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 15.14.1 Olanzapine versus olanzapine plus fluoxetine |
1 |
31 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.19 [0.01, 3.63] |
| 15.14.2 Fluoxetine versus fluoxetine plus olanzapine |
1 |
29 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.54 [0.05, 5.28] |
| 15.14.3 Valproic acid versus valproic acid plus eicosapentaenoic acid and docosahexaenoic acid |
1 |
43 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.29, 2.97] |
